Male metaplastic breast cancer with poor prognosis: A case report

Kim, Hyun Yul; Lee, Seungju; Kim, Dong-Il; Jung, Chang Shin; Kim, Jee Yeon; Nam, Kyung Jin; Choo, Ki Seok; Jung, Young-Dae

doi:10.12998/wjcc.v10.i15.4964

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 Excluding the lowgrade adenosquamous and fibromatosis-like variants, MBCs are often aggressive and chemoresistant. 2,3 Per literature review, there are only a handful of reported cases of male MBC [10][11][12][13][14][15] and to our knowledge, there is no recorded evidence of a male spindle cell breast cancer subtype. Male breast cancer is very rare, accounting for less than 1% of all cancers in men and less than 1% of all breast cancers.…”

Section: Discussionmentioning

confidence: 99%

KEYNOTE—522 and male spindle cell carcinoma of the breast: A case report

2023

View full text Add to dashboard Cite

Metaplastic Breast Cancer (MBC) is a rare group of tumors often presenting as triple-negative. MBC accounts for less than 1% of all breast cancers with the spindle cell variant comprising less than 0.5%. While rare, spindle cell carcinoma is the commonest subtype in the western world. It has a more aggressive biological behavior with increased risk of recurrence and death due to disease compared to triple negative breast cancers. There is no treatment guideline for management of MBC due to the rarity of the disease. Instead, treatment is theorized based off success with other types of aggressive breast and metaplastic cancers of different tissue. We present the first known case report of male spindle cell carcinoma of the breast treated with KEYNOTE-522 regimen. Therapy included a first phase with pembrolizumab (dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin and second phase, with four cycles of pembrolizumab with doxorubicin-cyclophosphamide.

show abstract

Section: Discussionmentioning

confidence: 99%

KEYNOTE—522 and male spindle cell carcinoma of the breast: A case report

2023

View full text Add to dashboard Cite

show abstract

“…The current understanding of metaplastic breast cancer involves comprehensive molecular profiling and histological evaluation to identify potential therapeutic targets. However, due to the rarity of the disease, clinical trials and evidence-based treatment guidelines specific to metaplastic breast cancer in male patients are scarce [ 6 , 7 ].…”

Section: Discussionmentioning

confidence: 99%

Unraveling Stigmas of Male Breast Carcinoma: A Singular Case of Advanced Metaplastic Breast Carcinoma in a Young Male

Kanwal,

Khalid,

Athar

et al. 2023

Cureus

View full text Add to dashboard Cite

Breast carcinoma in males is a rare and unique condition that differs from breast cancer in females and is typically diagnosed at an advanced stage in older male patients. Late diagnosis is often due to the rarity of male breast carcinoma. Among the various types of breast carcinomas, metaplastic breast carcinoma is one of the rarest kind of breast malignancy and is associated with poorer outcomes. This case report presents a singular case of a young male in his early thirties who presented with a breast lump and was diagnosed with metaplastic breast carcinoma. Breast cancer in males is a topic that is often overlooked and lacks extensive research. However, with an increasing incidence of breast carcinoma in males, including even the rarest forms, such as metaplastic carcinoma, and its occurrence in young patients as highlighted in this case report, it is crucial to initiate more discussions, enhance education, and promote further research in male breast carcinoma. In addition, the psychosocial impacts of the disease should be carefully considered, as men with breast cancer face unique emotional challenges that require attention and support.

show abstract